. 2021 Jun 10;7(6):e07265. doi: 10.1016/j.heliyon.2021.e07265

Table 2.

In-vitro antibacterial studies of synthesized ZnO nanoparticles.

S. No	Bacteria	Zinc oxide Nanoparticles Zone of inhibition (mm)
S. No	Bacteria	170 ± 2 ppm	100 ± 1 ppm	50 ± 1 ppm
Gram-negative
1	Sphingobacterium thalpophilum	3.2 ± 0.04^bc	2.7 ± 0.02^d	1.5 ± 0.05^cd
2	Staphylococcus aureus	3.2 ± 0.03^a	3.0 ± 0.05^a	2.4 ± 0.06^a
3	E. coli	3.7 ± 0.05^a	2.9 ± 0.04^abc	1.9 ± 0.07^c
4	Pseudomonas aeruginosa	3.5 ± 0.08^bc	3.2 ± 0.08^ab	3.1 ± 0.05^cd
5	Sphingobacterium sp	3.0 ± 0.06^a	2.9 ± 0.03^a	2.1 ± 0.16^a
6	Acinetobacter sp	2.8 ± 0.04^b	1.9 ± 0.04^d	1.4 ± 0.06^b
7	Ochrobactrum sp	2.7 ± 0.18^de	1.8 ± 0.13^a	1.2 ± 0.08^d
Gram-positive
8	Bacillus subtilis	2.7 ± 0.07^d	2.0 ± 0.04^b	0.9 ± 0.08^d
9	Streptococcus aureus	2.6 ± 0.02^d	1.6 ± 0.06^bc	1.1 ± 0.07^cd
10	Uncultured bacteriumFigure 8	2.9 ± 0.17^d	2.6 ± 0.06^abc	1.5 ± 0.09^d
	Completely Randomized Design CRD (P ≤ 0.05)	0.295	0.259	0.248

The data presented is ± SE of three measurements.

Data followed by the same letter are not significantly different at P ≤ 0.05, whereas those followed by different letters are significantly different at P ≤ 0.05.